Kezar Life Sciences, Inc.
http://kezarlifesciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kezar Life Sciences, Inc.
Kezar Puts All Its Eggs In One Basket
The group is instituting swingeing cuts to allow it to get to a mid-stage readout for zetomipzomib in lupus nephritis. What if the trial fails?
Asia Deal Watch: Inventiva Finds Japan/Korea Partner For Phase III NASH Candidate In Hepalys
Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.
Kezar’s Lead Asset Bounces Back With Lupus Win
Kezar’s lead asset zetomipzomib has demonstrated clinical significance in a mid-stage lupus trial just weeks after a disappointment in myositis but more robust data are needed for the first-in-class selective immunoproteasome inhibitor.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice